NL2025303B9 - Coronavirus targeting drugs - Google Patents
Coronavirus targeting drugs Download PDFInfo
- Publication number
- NL2025303B9 NL2025303B9 NL2025303A NL2025303A NL2025303B9 NL 2025303 B9 NL2025303 B9 NL 2025303B9 NL 2025303 A NL2025303 A NL 2025303A NL 2025303 A NL2025303 A NL 2025303A NL 2025303 B9 NL2025303 B9 NL 2025303B9
- Authority
- NL
- Netherlands
- Prior art keywords
- compound
- amino acid
- coronavirus
- nhc
- peptide
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 21
- 229940079593 drug Drugs 0.000 title description 5
- 230000008685 targeting Effects 0.000 title description 4
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 151
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 101
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 208000015181 infectious disease Diseases 0.000 claims abstract description 20
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 150000001413 amino acids Chemical group 0.000 claims description 94
- 241000711573 Coronaviridae Species 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 34
- 125000005647 linker group Chemical group 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 31
- -1 aminothioacids Chemical class 0.000 claims description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 241000315672 SARS coronavirus Species 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 150000002009 diols Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 3
- 150000007520 diprotic acids Chemical class 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 241000008904 Betacoronavirus Species 0.000 claims description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 2
- 238000012650 click reaction Methods 0.000 claims description 2
- 150000002023 dithiocarboxylic acids Chemical class 0.000 claims description 2
- 238000010930 lactamization Methods 0.000 claims description 2
- 238000005649 metathesis reaction Methods 0.000 claims description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims 3
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- RVEZZJVBDQCTEF-UHFFFAOYSA-N sulfenic acid Chemical class SO RVEZZJVBDQCTEF-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000005732 thioetherification reaction Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 25
- 235000001014 amino acid Nutrition 0.000 description 85
- 229940024606 amino acid Drugs 0.000 description 79
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 42
- 239000000203 mixture Substances 0.000 description 32
- 208000036142 Viral infection Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 230000009385 viral infection Effects 0.000 description 25
- 125000005842 heteroatom Chemical group 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 15
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- 229940096437 Protein S Drugs 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- QEQVUHQQYDZUEN-GUBZILKMSA-N Asn-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N QEQVUHQQYDZUEN-GUBZILKMSA-N 0.000 description 7
- YWLDTBBUHZJQHW-KKUMJFAQSA-N Asp-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N YWLDTBBUHZJQHW-KKUMJFAQSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 7
- 108010049041 glutamylalanine Proteins 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- MLZRSFQRBDNJON-GUBZILKMSA-N Gln-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MLZRSFQRBDNJON-GUBZILKMSA-N 0.000 description 6
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 6
- PHIXPNQDGGILMP-YVNDNENWSA-N Ile-Glu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PHIXPNQDGGILMP-YVNDNENWSA-N 0.000 description 6
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- QUUCAHIYARMNBL-FHWLQOOXSA-N Phe-Tyr-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N QUUCAHIYARMNBL-FHWLQOOXSA-N 0.000 description 6
- 101710198474 Spike protein Proteins 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 5
- 102100031673 Corneodesmosin Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010031318 Vitronectin Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229960005190 phenylalanine Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000004400 serine Nutrition 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N DL-isoserine Natural products NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229940000635 beta-alanine Drugs 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 108010077895 Sarcosine Proteins 0.000 description 3
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 3
- 150000001576 beta-amino acids Chemical class 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WNNNWFKQCKFSDK-SCSAIBSYSA-N (2r)-2-azaniumylpent-4-enoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC=C WNNNWFKQCKFSDK-SCSAIBSYSA-N 0.000 description 2
- YPJJGMCMOHDOFZ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-3-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CSC2=C1 YPJJGMCMOHDOFZ-ZETCQYMHSA-N 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 2
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 2
- JPSHPWJJSVEEAX-NFJMKROFSA-N (2s)-2-amino-4-fluoropentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(F)C(O)=O JPSHPWJJSVEEAX-NFJMKROFSA-N 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SXGMVGOVILIERA-UHFFFAOYSA-N 2,3-diaminobutanoic acid Chemical compound CC(N)C(N)C(O)=O SXGMVGOVILIERA-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- ZFUKCHCGMBNYHH-UHFFFAOYSA-N 2-azaniumyl-3-fluoro-3-methylbutanoate Chemical compound CC(C)(F)C(N)C(O)=O ZFUKCHCGMBNYHH-UHFFFAOYSA-N 0.000 description 2
- FNIVRLAVVDBWQZ-UHFFFAOYSA-N 2-azido-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)CC(C(O)=O)N=[N+]=[N-] FNIVRLAVVDBWQZ-UHFFFAOYSA-N 0.000 description 2
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 2
- VHVGNTVUSQUXPS-JAMMHHFISA-N 3-Phenylserine Chemical compound OC(=O)[C@@H](N)C(O)C1=CC=CC=C1 VHVGNTVUSQUXPS-JAMMHHFISA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
- XFGVJLGVINCWDP-UHFFFAOYSA-N 5,5,5-trifluoroleucine Chemical compound FC(F)(F)C(C)CC(N)C(O)=O XFGVJLGVINCWDP-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- INPQIVHQSQUEAJ-UHFFFAOYSA-N 5-fluorotryptophan Chemical compound C1=C(F)C=C2C(CC(N)C(O)=O)=CNC2=C1 INPQIVHQSQUEAJ-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 2
- KVNPSKDDJARYKK-JTQLQIEISA-N 5-methoxytryptophan Chemical compound COC1=CC=C2NC=C(C[C@H](N)C(O)=O)C2=C1 KVNPSKDDJARYKK-JTQLQIEISA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RHGKLRLOHDJJDR-SCSAIBSYSA-N D-citrulline Chemical compound OC(=O)[C@H](N)CCCNC(N)=O RHGKLRLOHDJJDR-SCSAIBSYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 2
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000018265 Virus Receptors Human genes 0.000 description 2
- 108010066342 Virus Receptors Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960001767 dextrothyroxine Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- VWHRYODZTDMVSS-QMMMGPOBSA-N m-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-QMMMGPOBSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-GDVGLLTNSA-N (2s)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical group CC(=O)N1CC(O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-GDVGLLTNSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HPBPNWPROCLLAA-UHFFFAOYSA-N 2-bromoethanone Chemical compound BrC[C]=O HPBPNWPROCLLAA-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- JZRBSTONIYRNRI-VIFPVBQESA-N 3-methylphenylalanine Chemical compound CC1=CC=CC(C[C@H](N)C(O)=O)=C1 JZRBSTONIYRNRI-VIFPVBQESA-N 0.000 description 1
- IRZQDMYEJPNDEN-UHFFFAOYSA-N 3-phenyl-2-aminobutanoic acid Natural products OC(=O)C(N)C(C)C1=CC=CC=C1 IRZQDMYEJPNDEN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- VBZOAGIPCULURB-QWRGUYRKSA-N Leu-Gly-His Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N VBZOAGIPCULURB-QWRGUYRKSA-N 0.000 description 1
- MVVSHHJKJRZVNY-ACRUOGEOSA-N Leu-Phe-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MVVSHHJKJRZVNY-ACRUOGEOSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BJBUEDPLEOHJGE-IUYQGCFVSA-N cis-3-hydroxy-D-proline zwitterion Chemical group O[C@H]1CCN[C@H]1C(O)=O BJBUEDPLEOHJGE-IUYQGCFVSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- ZHOBJWVNWMQMLF-UHFFFAOYSA-N n,n-bis(prop-2-ynyl)prop-2-yn-1-amine Chemical compound C#CCN(CC#C)CC#C ZHOBJWVNWMQMLF-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- TVIDEEHSOPHZBR-AWEZNQCLSA-N para-(benzoyl)-phenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C(=O)C1=CC=CC=C1 TVIDEEHSOPHZBR-AWEZNQCLSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- JDFUJAMTCCQARF-UHFFFAOYSA-N tatb Chemical compound NC1=C([N+]([O-])=O)C(N)=C([N+]([O-])=O)C(N)=C1[N+]([O-])=O JDFUJAMTCCQARF-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to compounds and to their medical use. Exemplary medical uses are the prevention and treatment of coronaVirus infections, such as SARS-CoV—Z infection. The compounds comprise at least two peptides that are physically linked through a linker, wherein each peptide comprises an amino acid sequence TFLDKFNHEAEDLFYQ or a variant thereof.
Description
P126846NL00 Title: CORONAVIRUS TARGETING DRUGS The invention relates to compounds and to their medical use.
Exemplary medical uses are the prevention and treatment of coronavirus infections, such as SARS-CoV-2 infection. The compounds comprise at least two peptides that are physically linked through a linker, wherein each peptide comprises an amino acid sequence TFLDKFNHEAEDLFYQ or a variant thereof.
In one aspect the invention relates to the use of compounds according to the invention in medical applications, particularly such as the treatment of coronavirus infections, by affecting the binding of the viral spike protein to a virus receptor of potential host cells.
Coronaviruses are known to cause diseases in mammals and birds, in particular infections to the respiratory tract. Whereas some coronaviruses, in particular human coronaviruses (HCoV), are typically responsible for common colds, other coronaviruses, such as Middle East respiratory syndrome-related coronaviruses (MERS) and severe acute respiratory syndrome-related (SARS) coronaviruses can be lethal.
A new coronavirus, which emerged in Wuhan, has resulted in a pandemic in early 2020. This severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), and the disease caused by it (COVID-19) is primarily lethal to aged patients with pre-existing medical conditions. The development of anti-coronavirus drugs is highly urgent as there is a great demand for such specific drugs, in particular to slow the SARS-CoV-2 pandemic and treat infected patients.
Studies aiming at developing coronavirus vaccines and anti-coronavirus therapies are diverse in the sense that varying viral targets or different stages of the disease are targeted. One such approach is directed to inhibitors of the so-called spike protein. Various attempts have been made to design spike protein inhibitors as a suitable starting point for further coronavirus disease treatment studies.
For example, Zhang ef al. (2020), bioRxiv (https://www.blorxiv.org/content/10.1101/2020.03.19.999318v1) relates to a chemically synthesized monomeric compound comprising 23-mer peptide fragment of an angiotensin-converting enzyme 2 (ACE2) peptidase domain (PD) al helix composed entirely of proteinogenic amino acids.
It is an objective of the invention to provide compounds that are suitable for use in medical applications, in particular with respect to inhibiting coronavirus infections, such as SARS-CoV-2 infections.
The inventors found that one or more of these objectives can, at least in part, be met by providing the compounds as described herein.
Accordingly, in a first aspect of the invention there is provided a compound, comprising at least two peptides that are physically linked through a linker, wherein each peptide comprises an amino acid sequence TFLDKFNHEAEDLFYQ or a variant thereof.
In a further aspect of the invention, there is provided a pharmaceutical composition comprising a compound as described herein.
In yet a further aspect of the invention, there is provided a compound as described herein for use as a medicament.
In yet a further aspect of the invention, there is provided a compound as described herein, such as the compound as described herein for use as a medicament, for use in the prevention or treatment of an infection caused by coronavirus.
In yet a further aspect of the invention, there is provided a method for inhibiting infection of a cell that is permissive for coronavirus, comprising: - providing the cell with a compound as described herein or a pharmaceutical composition as described herein.
In yet a further aspect of the invention, there is provided a method for treating an infection caused by a virus that can enter a cell via the ACE2 receptor, preferably a coronavirus in an individual, comprising: - administering a compound as described herein or a pharmaceutical composition as described herein to the individual.
In yet a further aspect of the invention, there is provided a method for treating an infection caused by a coronavirus in an individual, comprising: - administering a compound as described herein or a pharmaceutical composition as described herein to the individual.
When referring to a noun (e.g., compound, virus, virion, etc.) in the singular, the plural is meant to be included, or it follows from the context that it should refer to the singular only.
The term “alkyl” as used herein is meant to include optionally substituted straight (or linear) and branched chain alkyl groups that are saturated (i.e., no double or triple bonds present). The alkyl groups may have 1-20 carbon atoms. The alkyl groups may comprise one or more heteroatoms. In particular, the alkyl groups have 1-12 carbon atoms, such as 1-8 carbon atoms. Preferably, the alkyl groups have 1-6 carbon atoms.
The term also encompasses n-alkyl, zs0-alkyl (or i-alkyl), tert-alkyl (¢-alkyl), neo-alkyl, and anteisoalkyl groups. Substituted alkyl groups can be substituted with one or more substituents (e.g., substituents as described herein), such as amino, hydroxyl, cyano, carboxy, nitro, thio, alkoxy and/or halogen groups.
The term “alkenyl” as used herein is meant to include optionally substituted linear and branched chain and (poly)cyclic alkenyl groups having one or more double bonds. The alkenyl groups may have 2-20 atoms. The alkenyl groups may comprise one or more heteroatoms. In particular, the alkenyl groups can have 2-12 carbon atoms, such as 2-8 carbon atoms.
Preferably, the alkenyl groups have 2-6 carbon atoms. (Poly)cyclic alkenyl groups having one or more double bonds can have 3-12 ring members, such as 3, 5, 6, or 7. Preferably, (poly)cyclic alkenyl groups have 5, 6 or 7 ring members. The (poly)cyclic alkenyl groups may comprise one or more heteroatoms, such as oxygen, nitrogen, and/or sulfur. In particular, hetero(poly)cyclic alkenyl groups have 2-20 atoms of which 1-10 are heteroatoms, such as 2-12 atoms of which 1-6 are heteroatoms. Preferably, the hetero(poly)cyclic alkenyl groups have 2-8 atoms of which 1-4 are heteroatoms. Examples of cycloalkenyl groups include polycyclic ring structures as described herein having at least one double bond.
The term “alkynyl” as used herein is meant to include optionally substituted linear and branched alkyl groups having one or more triple bonds. The alkynyl groups may have 2-20 carbon atoms. The alkynyl groups may comprise one or more heteroatoms. In particular, the alkynyl groups can have 2-15 carbon atoms. Preferably, alkynyl groups have 2-10 carbon atoms, such as 2, 3, 4, 5, or 6.
The term “aryl” as used herein is meant to include optionally substituted monocyclic, bicyclic and polycyclic (e.g., having 2, 3 or 4 rings that can be fused) aromatic hydrocarbon groups. The aryl groups may comprise one or more heteroatoms. The aryl groups may have 5-20 carbon atoms. In particular, the aryl groups can have 5-10 carbon atoms. Preferably, the aryl groups have 5 or 6 carbon atoms. The term “aryl” is also meant to include substituted aromatic hydrocarbons, that can be monosubstituted or substituted more than once, such as 2-, 3-, 4-, 5-, or 6- substituted, or di-substituted.
The term “compound”, in particular in the case of the compound according to the invention, is meant to include all possible atropisomers, stereoisomers, diastereomers, optical stereoisomers, tautomers, as well as mixtures thereof, including racemic mixtures. Depending on the desired use of the compound, a pure compound, racemic mixture, or mixture having varying isomer ratios may be selected. The term also includes solvates, such as hydrates, as well as anhydrous and non-solvated forms. Also, the term includes all isotopes of atoms occurring in the intermediate compounds and/or (final) compounds (products). The compound may also exist as a solvate, z.e., a compound in a composition with solvent molecules. In that 5 case, the composition includes solvent in stoichiometric quantities, such as a monosolvate or a disolvate, or can include solvent in random amounts. In case the solvent 1s water, the term “solvate” may be read as “hydrate”.
The term “cycloalkyl” as used herein is meant to include optionally substituted, partly saturated, and completely saturated non-aromatic cyclic hydrocarbons. The cycloalkyl groups can have up to 20 ring-forming atoms. In particular, the cycloalkyl groups may predominantly comprise carbon atoms, and optionally contain one or more heteroatoms, such as oxygen, sulfur, and nitrogen as part of the cycle. The cycloalkyl groups can have 3-12 ring members, such as 3, 4, 5, 6 or 7.
Cycloalkyls include mono- or polycyclic ring structures, such as fused ring systems, bridged ring systems and spiro ring systems. Cycloalkyl groups also include rings that are substituted with linear or branched chain alkyl groups as defined herein. Examples of substituted cycloalkyl groups can be mono-substituted or substituted more than once, such as 2,2-, 2,3-, 2,4-, 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted polycyclic groups, which can be substituted with, for example, amino, hydroxyl, cyano, carboxy, nitro, thio, alkoxy, and/or halogen groups.
The term “haloalkyl” as used herein is meant to include optionally substituted mono-halo alkyl groups and poly-halo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms. The haloalkyl groups may comprise one or more heteroatoms.
The term “heteroatom” as used herein is meant to refer to an atom other than hydrogen or carbon. In particular, the heteroatom can be an oxygen atom, a sulfur atom, a nitrogen atom, a phosphorus atom, or a boron atom.
Preferably, the heteroatom is a trivalent atom, such as nitrogen atom or boron atom.
More preferably, the heteroatom is nitrogen atom.
The term “heteroalkyl” as used herein is meant to include optionally substituted linear or branched chain alkyl groups consisting of a number of carbon atoms and at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur.
In particular, heteroalkyl groups can have 1-20 carbon atoms and/or 1-10 heteroatoms, such as 1-12 carbon atoms and/or 1-8 heteroatoms.
Preferably, the heteroalkyl groups have 1-8 carbon atoms and/or 1-4 heteroatoms.
The nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quarternized (i.e., four substituents each having a carbon bond to the nitrogen atom, substituted ammonium groups, or salts). The heteroatom may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the moiety to which 1t1s attached, as well as attached to a distal carbon atom, such as the most distal one, in the heteroalkyl group.
The term “heteroaryl” as used herein is meant to include optionally substituted aromatic heterocycles having, for example, ring-forming atoms (particularly mostly carbon atoms) and having at 20 least one heteroatom ring member, such as a sulfur atom, an oxygen atom, or a nitrogen atom.
The term includes monocyclic and polycyclic (e.g. having 2, 3 or 4 fused rings) systems.
The term “heterocycloalkyl” as used herein is meant to include optionally substituted non-aromatic heterocyclic alkyls that can have up to 20 ring-forming atoms.
Exemplary heterocycloalkyl groups are cyclic alkyls, cyclic alkenyls, and cyclic alkynyls having one or more of the ring-forming carbon atoms replaced by a heteroatom, such as oxygen, nitrogen, and/or sulfur atom.
Heterocycloalkyls can be mono or polycyclic (e.g., fused, bridged, or spiro) systems.
Also included by the term are functional groups that have one or more aromatic rings fused (i.e., having a bond in common) to a non-aromatic heterocyclic ring.
The phrase “in need thereof” as used herein is meant to include that a subject has been identified as having a need for the particular method or treatment. The identification of such a need can be by any means of diagnostics. In particular, in any of the methods and treatments described herein, the subject is in need thereof.
The term “individual” as used herein is meant to include the human and animal body, preferably the human body. The term is meant to be interchangeable with “subject” and “patient”. The term “animal” is meant to exclude humans, and to include non-humans, such as vertebrates, e.g., wild, domestic, and farm animals.
The phrase “optionally substituted” as used herein is meant to refer to the optional presence of one or more substituents, such as the substituents as described herein.
The terms “prevention” and “preventing” as used herein are meant to refer to a reduction of the risk of acquiring a particular infection, disease, condition, or disorder.
The term “substituent” as used herein is meant to refer to an organic group, such as a heteroatomic organic group, or a halogen that substitutes at least one atom or one atomic group of another molecule. For example, a hydrogen bond present in a molecule may be replaced by a bond to a non-hydrogen atom which originates from a(n) (indicated) substituent. Exemplary bonds to a non-hydrogen atom include bonds to a halogen atom, a carbon atom or an oxygen atom. These can include groups such as hydroxyl groups, alkoxy groups, aryloxy groups, arylalkoxy groups, oxo(carbonyl) groups, carboxyl groups, such as carboxylic acids, carboxylates, and carboxylate esters, a sulfur atom in groups, such as thiol groups, thioalkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups, a nitrogen atom in groups, such as amines, hydroxylamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines, a carbon atom in groups, such as those described herein such as alkyl groups such as methyl, ethyl, propryl or butyl groups and aryl groups, cycloalkyl groups, alkenyl groups, alkynyl groups, alkoxy and aryloxy groups, and other atoms in various other groups.
Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more hydrogen bonds are replaced by one or more bonds, including double or triple bonds, to a carbon atom, or to a heteroatom, such as oxygen in (oxo)carbonyl, carboxyl, ester, amide, imide, urethane, and urea groups, and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines and nitriles.
Substituted ring groups, such as substituted cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a substituted alkyl, alkenyl, or alkynyl group as defined herein.
Suitable halogen substituents include fluorine, chlorine, bromine, and iodine, preferably fluorine.
The phrase ”(therapeutically) effective amount” as used herein is meant to refer to the amount of active compound that elicits the biological or medicinal response that is being sought in a tissue, system or subject by a researcher, veterinarian, medical doctor or other clinician (practitioner). The therapeutic effect is dependent upon the disorder being treated, the biological effect desired, or the clinical result desired.
As such, the therapeutic effect can be a decrease in the severity of symptoms associated with the disorder and/or inhibition (partial or complete; at least in part) of the progression of the disorder, or improved treatment, healing, prevention or elimination of a disorder, or side-effects.
The amount needed to elicit the therapeutic response can be determined, for example, based on the species, age, health, size, gender and/or sex of a subject.
Optimal amounts can also be determined based on monitoring of the subject’s response to treatment.
The terms “treatment” and “treating” as used herein are not meant to be limited to curing. Treating is meant to also include alleviating at least one symptom of a disease, removing at least one symptom of a disease, lessen at least one symptom of a disease, and/or delaying the course of a disease. The term “treatment” as used herein is also meant to include methods of therapy and diagnosis. Also, the terms are meant to include therapeutic treatment and prophylactic or preventative measures wherein the object 1s to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or obtain beneficial or desired clinical results.
Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of condition, disorder or disease, stabilized (i.e. not worsening) state of condition, disorder or disease, delay in onset or slowing of condition, disorder or disease progression, amelioration of the condition, disorder or disease state or remission (whether partial or total), whether detectable or undetectable, an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. Thus, “treatment of a viral infection” or “treating a viral infection” means an activity that prevents, alleviates or ameliorates any of the symptoms associated with the specific viral infection and infectious diseases.
The phrase “treating a viral infection” or “treatment of a viral infection” also refers to the treatment of a subject infected with a virus that is capable of causing an infection or has already caused an infection. The treatment can (selectively) target virions.
The terms “virion” and “virus” as used herein are used interchangeably.
The terms “N-terminus” and “C-terminus” as used herein are meant to also include side chains or non-natural amino acids in the N- or C- terminal part (such as the terminal 4 or 3 amino acids) of the peptides.
The invention provides a compound, comprising at least two peptides that are physically linked through a linker, wherein each peptide comprises an amino acid sequence TFLDKFNHEAEDLFYQ or a variant thereof. In particular, each peptide is attached via its N-terminus and/or C-terminus to the linker.
The compound as described herein comprises at least two peptides having an amino acid sequence TFLDKFNHEAEDLFYQ or a variant thereof. In particular, the compound comprises 2 peptides, such as 3 or more, 4 or more, or 5 or more. Preferably, the compound comprises 2 or 3 peptides. More preferably, the compound comprises 3 peptides.
The compound may comprise two peptides, wherein both peptides are attached to the linker via their N-terminus; both peptides are attached to the linker via their C-terminus, or one peptide is attached to the linker via its N-terminus and the other peptide 1s attached to the linker via its C-terminus. In case the compound comprises three peptides, every peptide may be attached to the linker via their N-terminus; every peptide may be attached to the linker via their C-terminus; two peptides may be attached to the linker via their N-terminus and one peptide may be attached to the linker via its C-terminus, or two peptides may be attached to the linker via their C-terminus and one peptide may be attached to the linker via its N-terminus.
The peptides of the compound as described herein may be all isolated peptides, all synthetic, all recombinant peptides, or any combination of isolated, synthetic and recombinant peptides. For example, the compound may comprise one isolated peptide and two synthetic peptides. The peptides comprise at least an amino acid sequence TFLDKFNHEAEDLFYQ or a variant thereof. The peptides may comprise an amino acid sequence IEEQAKTFLDKFNHEAEDLFYQSSLA or a variant thereof.
The variant of the amino acid sequence may have at least 16 amino acids, preferably based on TFLDKFNHEAEDLFYQ, or at least 26 amino acids, preferably based on IEEQAKTFLDKFNHEAEDLFYQSSLA.
Either variant may further have one or more amino acids selected from L, I, V or A, substituted by another amino acid selected therefrom, one or more amino acids substituted by their corresponding D-amino acid, and/or one or more amino acids substituted by a corresponding non-natural amino acid.
In one embodiment one or more of the peptide further comprises one or more additional amino acids.
In one embodiment the additional amino acids comprise the sequence LGKGDFR (reflecting amino acid 351-357 of human ACE2 (Uniprot accession Q9BYF1). The additional LGKGDFR amino acids are preferably on the C-terminal side of the peptide, preferably associated with the peptide via a connector.
Examples of such peptides are described in Han et al. (2006, Virology 350: 15-25). The connector is preferably one or a short stretch of 2, 3 or 4 amino acids in peptide linkage with each other and the flanking amino acids.
In Han et al. (2006, Virology 350: 15-25) the connector is a glycine.
In peptides that are linked to the linker via their N-terminus, the connector is preferably one or two amino acid(s) in peptide linkage with the peptide and the additional LGKGDFR amino acids.
The one or two amino acid(s) are preferably one or two glycines, one or two beta-alanines or a combination of a glycine and a beta-alanine.
Peptides that comprise the additional LGKGDFR amino acids preferably have a sequence of at least the amino acids TFLDKFNHEAEDLFYQ preferably the amino acids IEEQAKTFLDKFNHEAEDLFYQSS.
In this last embodiment the connector is in peptide linkage with the C-terminal S and is preferably a glycine or a beta-alanine.
The connector amino acid is preferably in peptide linkage with the L of the additional LGKGDFR amino acids.
Non-limiting examples of suitable peptide-connector-additional LGHKGDFR amino acids peptides are IEEQAKTFLDKFNHEAEDLFYQSS-G-LGKGDFR; IEEQAKTFLDKFNHEAEDLFYQSS-betaA-LGKGDFR; and IEEQAKTFLDKFNHEAEDLFYQSS-GG-LGKGDFR, wherein betaA stands for beta-alanine and the “-* have no physical meaning but are indicated solely for illustrative purposes.
In peptides that are linked to the linker via their C-terminus, the connector is preferably one or two amino acid(s) in peptide linkage with the peptide and the additional LGKGDFR amino acids. The one or two amino acid(s) are preferably lysine and/or glycine. Peptides having the additional LGKGDFR amino acids that are linked to the linker via their C-terminus are preferably linked to the linker via a direct linkage of the linker to the connector. Non-limiting examples of suitable peptide-connector-additional LGHKGDFR amino acids peptides are IEEQAKTFLDKFNHEAEDLFYQSS-GL(PEG-SH)-LGKGDFR; and IEEQAKTFLDKFNHEAEDLFYQSS-L(PEG-SH)G-LGKGDFR wherein (PEG-SH) means a PEG-moiety attached to the lysine side-chain including a thiol modification for easy association with the linker.
A variant of the peptide TFLDKFNHEAEDLFYQ or IEEQAKTFLDKFNHEAEDLFYQSSLA preferably has up to 5 of the following amino acid substitutions: substitution of one or more amino acids selected from the group of L, I or A by another amino acid selected from L, I, V or A; substitution of one or more amino acids selected from the group of Kor H by an amino acid selected from R, Kor H; substitution of E by Q substitution of Y by F substitution of one or more amino acids selected from the group of Q.N, A, S or T by another amino acid selected from said group;
having one or more substitutions of an amino acid by a corresponding D-amino acid, having up to 5 substitutions of an amino acid by a corresponding non-natural amino acid, and/or having a retro-inverso sequence of at least 16 consecutive amino acids from said amino acid sequence.
A variant of the peptide TFLDKFNHEAEDLFYQ such as IEEQAKTFLDKFNHEAEDLFYQSSLA preferably has up to 5 of the following amino acid substitutions: substitution of one or more amino acids selected from the group of L, I or A by another amino acid selected from L, I, V or A; substitution of one or more amino acids selected from the group of K or H by an amino acid selected from R, K or H; substitution of E by Q substitution of Y by F substitution of one or more amino acids selected from the group of Q, N, A, S or T by another amino acid selected from said group; having one or more substitutions of an amino acid by a corresponding D-amino acid, having up to 5 substitutions of an amino acid by a corresponding non-natural amino acid, and/or having a retro-inverso sequence of at least 16 consecutive amino acids from said amino acid sequence.
Variants of the peptides TFLDKFNHEAEDLFYQ or TEEQAKTFLDKFNHEAEDLFYQSSLA preferably have 1, 2, 3 or 4 of the described amino acid substitutions. Preferably a variant has 1, 2 or 3 of the described amino acid substitutions, more preferably 1 or 2, more preferably 1 of the described amino acid substitutions.
Variants of the peptide TFLDKFNHEAEDLFYQ that are 16-26 amino acids long preferably have a consecutive sequence of the peptide
IEEQAKTFLDKFNHEAEDLFYQSSLA, or a variant having up to 1, 2, 3 or 4 of the described amino acid substitutions.
A variant of peptide or amino acid sequence TFLDKFNHEAEDLFYQ or IEEQAKTFLDKFNHEAEDLFYQSSLA as defined herein may comprise up to 5 substitutions of an amino acid by a corresponding non-natural amino acid. “Non-natural amino acids” as used herein refers non-genetically encoded amino acids, irrespective of whether they appear in nature or not.
Non-natural amino acids that can be present in a variant of an amino acid sequence as defined herein include: beta-amino acids; p-acyl-L-phenylalanine; N-acetyl lysine; O-4-allyl-L-tyrosine; 2-aminoadipic acid; 3-aminoadipic acid; beta-alanine; 4-tert-butyl hydrogen 2-azidosuccinate; beta-aminopropionic acid; 2-aminobutyric acid; 4-aminobutyric acid; 2, 4,-diamino butyric acid; 6-aminocaproic acid; 2-aminoheptanoic acid; 2-aminoisobutyric acid; 3-aminoisobutyric acid;
2-aminopimelic acid; p-aminophenylalanine; 2,3-diaminobutyric acid; 2,3-diamino propionic acid; 2,2'-diaminopimelic acid; p-amino-L-phenylalanine; p-azido-L-phenylalanine; D-allylglycine; p-benzoyl-L-phenylalanine; 3-benzothienyl alanine p-bromophenylalanine; t-butylalanine; t-butylglycine; 4-chlorophenylalanine; cyclohexylalanine;
cysteic acid; D-citrulline; thio-L-citrulline; desmosine; epsilon-amino hexanoic acid; N-ethylglycine; N-ethylasparagine; 2-fluorophenylalanine; 3-fluorophenylalanine; 4-fluorophenylalanine; homoarginine; homocysteine; homoserine; hydroxylysine; allo-hydroxylysine; 3-(3-methyl-4-nitrobenzyl)-L-histidine methyl ester; isodesmosine;
allo-isoleucine; isopropyl-L-phenylalanine; 3-methyl-phenylalanine; N-methylglycine; N-methylisoleucine; 6-N-methyllysine; O-methyl-L-tyrosine; N-methylvaline; methionin sulfoxide; 2-napthylalanine; L-3-(2-naphthyl)alanine; isoserine; 3-phenylserine; norvaline; norleucine; 5,5,5-trifluoro-DL-leucine; ornithine;
3-chloro-tyrosine; N5-carbamoylornithine; penicillamine; phenylglycine;
piperidinic acid; pyridylalanine; 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid; beta-2-thienylalanine; y-carboxy-DL-glutamic acid; 4-fluoro-DL-glutamic acid; D-thyroxine; allo-threonine; 5-hydroxy-tryptophan; 5-methoxy-tryptophan; 5-fluoro-tryptophan; 3-fluoro-valine.
In one embodiment, a natural amino acid of said sequence is substituted by a corresponding non-natural amino acid. As used herein, a “corresponding non-natural amino acid” refers to a non-natural amino acid that is a derivative of the reference natural amino acid. For instance, a natural amino acid is substituted by the corresponding beta-amino acid. Beta-amino acids have their amino group bonded to the beta carbon rather than the alpha carbon as in the natural amino acids. Examples of substitution of a natural amino acid by a non-natural amino acid that is a derivative of said natural amino acid are the following. Alanine is for instance substituted by beta-alanine, t-butylalanme, 2-napthylalanine; L-3-(2-naphthyDalanine, 2-aminoisobutyric acid. Arginine is for instance substituted by homoarginine, ornithine, N5-carbamoylornithine, 3-amino-propionic acid. Asparagine is for instance substituted by N-ethylasparagine. Aspartic acid is for instance substituted by 4-tert-butyl hydrogen 2-azidosuccinate. Cysteine is for instance substituted by cysteic acid, homocysteine. Glutamic acid is for instance substituted by y-carboxy-DL-glutamic acid; 4-fluoro-DL-glutamic acid. Glutamine is for instance substituted by D-citrulline, thio-L-citrulline. Glycine is for instance substituted by N-methylglycine, t-butylglycine, N-methylglycine, D-allylglycine. Histidine is for instance substituted by 3-(3-methyl-4-nitrobenzyl)-L-histidine methyl ester. Isoleucine is for instance substituted by isodesmosine, N-methylisoleucine, allo-isoleucine. Leucine is for instance substituted by norleucine, desmosine, 5,5,5-trifluoro-leucine. Lysine is for instance substituted by 6-N-methyllysine, 2-aminoheptanoic acid, N-acetyl lysine, hydroxylysine,
allo-hydroxylysine. Methionine is for instance substituted by methionin sulfoxide. Phenylalanine is for instance substituted by p-amino-L-phenylalanine, 3-benzothienyl alanine p-bromophenylalanine, p-acyl-L-phenylalanine, 2-fluorophenylalanine, 3- fluorophenylalanine, 4-fluorophenylalanine. Proline is for instance substituted by 3-hydroxyproline, 4-hydroxyproline, 1-acetyl-4-hydroxy-L-proline. Serine is for instance substituted by homoserine, isoserine, 3-phenylserine. Threonine is for instance substituted by D-thyroxine, allo-threonine. Tryptophan is for instance substituted by 5-hydroxy-tryptophan, 5-methoxy-tryptophan, 5-fluoro-tryptophan. Tyrosine is for instance substituted by O-methyl-L-tyrosine, O-4-allyl-L-tyrosine, 3-chloro-tyrosine. Valine is for instance substituted by norvaline, N-methylvaline, 3-fluoro-valine.
In amino acid sequences or variants thereof as defined herein amino acids are denoted by single-letter symbols. These single-letter symbols and three-letter symbols are well known to the person skilled in the art and have the following meaning: A (Ala) is alanine, C (Cys) is cysteine, D (Asp) 1s aspartic acid, E (Glu) 1s glutamic acid, F (Phe) is phenylalanine, G (Gly) 1s glycine, H (His) is histidine, I (Ile) is isoleucine, K (Lys) is lysine, L (Leu) 1s leucine, M (Met) is methionine, N (Asn) is asparagine, P (Pro) is proline, Q (Gln) is glutamine, R (Arg) is arginine, S (Ser) is serine, T (Thr) is threonine, V (Val) 1s valine, W (Trp) 1s tryptophan, Y (Tyr) is tyrosine.
A peptide of the invention may comprise non-peptidic structural elements. Such non-peptidic structural elements may be present in the amino acid sequence TFLDKFNHEAEDLFYQ), TEEQAKTFLDKFNHEAEDLFYQSSLA, or in a variant thereof as defined herein, as a result of substitution of modification of one or more amino acids of said sequence or variant. Alternatively, a peptide of the invention may comprise non-peptidic structural elements outside the amino acid sequence TFLDKFNHEAEDLFYQ or IEEQAKTFLDKFNHEAEDLFYQSSLA or in a variant thereof as defined herein, i.e. in the optional N- and/or C-terminal elongating groups. A non-peptidic structural element is typically a modification of one or more existing amino acids. Preferred peptidomimetics are obtained by structural modification of a peptide as described herein, for instance using non-natural amino acids such as defined herein above, conformational restraints, cyclization of the polypeptide, isosteric replacement or other modifications. The amino acid sequence of a peptide according to the invention thus optionally comprises one or more modifications. Such peptide may be modified by natural processes, such as posttranslational processing, or by chemical modification techniques.
Modifications may be inserted at any location in said peptide, including in the peptide backbone, amino acid side-chains and at the N- or C-terminus. A single peptide may contain multiple types of modifications or several modification of a single type. Modifications include acetylation, amidation, acylation, phosphorylation, methylation, demethylation, ADP-ribosylation, disulfide bond formation, ubiquitination, gamma-carboxylation, glycosylation, hydroxylation, iodination, oxidation, pegylation and sulfation. In addition a peptide as described herein may be provided with a label, such as biotin, fluorescein or flavin, a lipid or lipid derivative, a sugar group.
The alpha-helical character of the peptides may be increased and/or stabilized by introducing one or more intramolecular crosslinks. The o-helix features 3.6 residues per complete turn, which places side chains at positions i, i+4, and i+7 on the same face of the folded structure. Preferably, the alpha-helical conformation in peptides employs one or more crosslinks between amino acids at positions z and z+4 or z and +7. Amino acid positions suitable for crosslinks between the z and i+4 side chain groups include 21/25, 22/26, 25/29, 28/32, 29/33, 32/36, 36/40, 39/43, and 40/44. Amino acid positions suitable for crosslinks between the i and +7 side chain groups include 21/28, 22/29, 25/32, 26/33, 29/36, 32/39, 33/40, 36/43, and 39/46. Well-known side chain crosslinks used for stabilizing peptide alpha-helices can be obtained via lactamization, thioether formation, click reactions and metathesis. Each of these can be employed in the present invention. Some illustrative examples are shown in Figure 1.
The compound as described herein comprises a linker which may comprise any of a trivalent atom, preferably a trivalent atom, such as nitrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
The compound as described herein may be a compound of formula (D or (II), wherein the formulas are DI), ma ERR wherein m and n are, independently, integers of 1-100; 01s at least 1; V and Y are spacers, independently, derived from amino acids, amino thioacids, diprotic acids, such as dicarboxylic acids and dithiocarboxylic acids, diols, such as glycols, and/or mercapto alcohols; Wis - a multivalent atom, preferably a trivalent atom, such as nitrogen, optionally substituted linear or branched alkyl, optionally substituted linear or branched heteroalkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched heteroalkenyl, optionally substituted linear or branched alkynyl, optionally substituted linear or branched heteroalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or - CR3 or SiR?, wherein R3 hydrogen or a label, such as a PEG label, a fluorescent label, an isotope, or a bio-orthogonal handle; X is optionally substituted linear or branched alkyl, optionally substituted linear or branched heteroalkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched heteroalkenyl, optionally substituted linear or branched alkynyl, optionally substituted linear or branched heteroalkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl; and Z 1s a peptide as described herein, wherein Z is attached to Vor Y via N-terminus and/or C-terminus.
Preferably, “m” and “n” in formula (I) or (II) are, independently, integers of 2-10, such as 2, 4 or 6. Preferably, “0” in formula (I) is 2 or 3, and more preferably 3.
The V and Y in formula (I) or (II) may be, independently, derived from amino acids and/or diols. In particular, the V and Y are, independently, derived from diols, such as linear diols, e.g., ethylene glycol, linear amino acids, such as 4-aminobutyric acid, 5-aminovaleric acid and 6-amino-hexanoic acid, a-amino acids and/or B-amino acids selected from arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, glycine, proline, alanine, valine, isoleucine, leucine, methionine, phenylalanine, ornithine, tyrosine, tryptophan, and derivatives thereof. Preferably, V and Y are, independently, glycine, serine and/or ethylene glycol.
The compound as described herein may have any of the following formulas:
z Er AEN { he “Bw Xx Bw DN NI x x 1, 1, DV], z (Ia), z (Ta-H), z (Ib), z A Nx VIX 2 " \ Hx { \ d= Ii N X ” Se] MI, z (Ib-H), z (Ic),
A LY] z Xx x] 9 ” Saga z—fy m= + i (Ic-H-0), 1, ° (Ic-H-m), 72 =, (Te-Hop), wherein X comprises —(CH2)2:NHC(=0)CH:—, —-CH2NHC(=0)(CH2)2—, -CH:NHC@=0)CH--, —(CH2)2NHC(=0)(CH3)2—, —C(=0)CH:2NHC(=0)CH.—, —C(=0)CH3z—, —C(=0)(CHs)2—, -NHS(=0)2(CH3)s—, -NHS(=0)2CH2—, —(CH2):NHS(=0)2(CHz)2—, -CH:NHS(=0)4(CHs)2-, -(CH;)2NHS(=0):CHa-, -CH:NHS(=0):CH:-, -C@=0)CH:NHS(=0):CH:-, —C(=0)CH:NHS(=0)2(CHz)2—, -C=0)(CH2):NHS(=0)2CHs-, -C=0)(CH;)2NHS(=0})2(CH>)2-, -S=0)2CHs-, -CHsS(=0)2CHs-, -S(=0)2(CH>):-, -CH:58=0)24(CH2)2-, —(CH2)2S(=0)2(CHe)2—, —(CH3)2:NHC(=0)(CH)2CHgz—, —CH2NHC(=0)(CH)2(CHz)2—,
—(CHy):NHC(=0)(CH)2(CHs)2—, -CH2NHC(=0)(CH)2:CH2—, —C(=0)CH:2NHC(=0)(CH)2CH2—, —C(=0)CH:2NHC(E=0O)CH)2(CHz)2—, -CEO)CH>):NHCEO)CH):CH:, —C(=0)(CH2)2NHC(=0)(CH)2(CHz)2—, —C(=0)(CH):CH2—, —C(=0)(CH)2(CHzy)2—, -NHP=OXOR)(CH:)2-, -NHPEO)XOR)(CCH):-, -NHC(=0)(CH)2CHz—, -NHC(=0)(CH)2(CHy)2—, Dee ASSN <A, -NHC@O)N=S(CH;)-, -C=O)NH-, NN optionally RE ho N== A += I Ny 8 wy No substituted * , Ä — NA Ro or derivatives thereof, wherein R'is alkyl, cycloalkyl or aryl, and R71s hydrogen, alkyl, cycloalkyl or aryl; Wis N, CR? or SiR3; R3 is hydrogen or a label, such as a PEG label, a fluorescent label, an isotope, or a bio-orthogonal handle; and QisCH or N or wherein the compound has one of the following formulas: se Oc nz (a) or z A A z my pik Ny a, wherein n is an integer of 1-100, preferably 2-10; L is amino acid, preferably glycine and/or serine, and A comprises -NHC(=0)CHsz-, -CHsNHC{=0)-, -CH:NHC{=0)CH:, -CH:NHCEO)(CHs):-, -(CH>2NHC(=0)CH:-, —(CH3z)2NHC(=0)(CHg)2—, -CHCHeNHC(=0)CH:-, -CH:sNHC(=0)CH:CH-,
—CH:NHC(E=0)(CH2)2:CH—, -CH(CH2):NHC(=0)CH:—, 0 Sx “IN / —CH(CHg2):NHC(=0)(CHz)>—, © , or derivatives thereof; m is an integer of 1-100, preferably 2-10; Y is a spacer, preferably derived from amino acids, amino thioacids, diprotic acids, such as dicarboxylic acids and dithiocarboxylie acids, diols, such as glycols, and/or mercapto alcohols, and Z is a peptide as described herein.
The compound as described herein may have any of the following formulas: 9 0 NH-Z 8 Io.
Y wi fo N Rh 2 2 A So SET woo Ly o 9 3 o Ao NE Po AS 0 3 (Id-C1), ? o Nez nA Ao o | = 1 oO o N O- ; | o Ax ~~ 1 o So _ ~~ PR 3 Sy z wo DNH o (Id-C2),
1 0 cor? Nhe oP} 3 0 NN he
NN TN N— Ln o 4 / LN er 0h VZ on 4 3 NE Po NH ~cor* 0 3 (Id-C3), o o | i s7 ef do zoo oy 3 o o il 4 NN fF oH zon oy 7 Î eo 3 1 i Ak dn zoo" (Id-N1), o 0 i ak zoon ox N= and Oo ~0 Sd ho 0 o = © ay 5 (Id-N2), or oo , 0 Oo nzo! HN 32 9 Nez / I “Gon “NH-Z-coRr* N NH 5 ie / 7°
A ¢N N-N La ee nez-cort “Lo 5 (Id-N3), wherein Z is as defined above, and each R4 is independently OH or NH:.
There is also provided herein a pharmaceutical composition comprising a compound as described herein.
In an embodiment, the pharmaceutical composition comprises one or more compounds of formula (I) or (IT) as described herein, for example, one or more compounds of any of formulas Ia, Ia-H, Ib, Ib-H, Ie, Ic-H-o, Ic-H-m, Ic-H-p, Ila, Ib, Id-C1, Id-C2, Id-C3, Id-N1, Id-N2, or Id-N3.
The compound as described herein, including the compounds according to any of the formulas depicted herein, and the pharmaceutical composition as described herein, may be used in medical applications, such asin medicine, for example, as a medicament, such as a pharmaceutical.
The compound as described herein may be used for treating a medical disorder (i.e., a disease, condition or symptom(s)), especially coronavirus infections. The compound and the pharmaceutical composition as described herein may be for use in the prevention or treatment of a viral infection, such as an infection caused by coronavirus.
In particular, the coronavirus as described herein utilizes the ACE2 receptor for entry into a cell. Coronaviruses, such as SARS-CoV and SARS-CoV-2 initiate entry into human cells by targeting ACE2 which forms a heterotetrameric transmembrane complex with BVAT1. It is believed that the virus protein responsible for this interaction is the spike protein (S- protein) which binds ACE2 via its receptor binding domain (RBD). The S- proteins of inter alia abovementioned coronaviruses are homologous and target the analogous site on ACE2. The entry-process is central to the virulence of coronaviruses. Hence, the inventors designed high-affinity compounds as described herein that bind to the RBD of the S-protein thereby inhibiting the interaction between the virion and the human host cell. The S-protein is exposed on the outside of the viral capsid. The RBD adopts two possible conformations with the S-proteins, i.e., closed or open (Figure 2). Further analysis led the inventors to believe that additional conformations can be expected, such as two-open and all-open conformations
(Figure 2D). Coronavirus binds to ACE2 via the RBD of the S-protein. A CryoEM structure of the complex between the B9AT1-ACE2 receptor and the RBD was reported in the art (Figure 2B). The structure reveals an o- helix in ACE2 that is believed to mediate most of the contacts with the RBD. The helical ACE2-derived interaction motif comprises 26 amino acids (IEEQAKTFLDKFNHEAEDLFYQSSLA) (Figure 2C). Overlaying the RBD bound to the ACE2-derived helix with the closed or all-open S-protein structures provides two distinct helix orientations for either conformation. For the open conformation the helix C-termini point towards each other, while for the closed conformation the N-termini point towards each other. Based on the above surprising observation, the inventors designed the herein described compound as suitable spike protein-targeting peptide- based inhibitors of which the C-terminal linked peptides target the closed conformation, whereas the N-terminal linked peptides target the all- or partially open conformations.
The coronavirus as described herein may be any coronavirus, such as a betacoronavirus. Preferably, the coronavirus is a severe acute respiratory syndrome-related coronavirus or a Middle East respiratory syndrome-related coronavirus. More preferably, the coronavirus is SARS-CoV, SARS-CoV-2 or MERS-CoV. In a particularly preferred embodiment the coronavirus is SARS-CoV or SARS-CoV-2, preferably SARS-CoV-2. Viral infections, such as coronavirus infection, as described herein, may refer to an infection in any part of the individual's (body), in particular the respiratory and gastrointestinal tracts or part(s) thereof.
A medical use or medical method of a compound as described herein is preferably a use or method for the treatment of an individual that is infected or suspected of being infected by a virus that can enter a cell via the ACE2 receptor (not excluding additional target receptors). In a preferred embodiment the virus is a coronavirus, preferably a severe acute respiratory syndrome-related coronavirus or a Middle East respiratory syndrome-related coronavirus. More preferably, the coronavirus is SARS-CoV, SARS-CoV-2 or MERS-CoV. In a particularly preferred embodiment the coronavirus is SARS-CoV or SARS-CoV-2, preferably SARS-CoV-2. Viral infections, such as coronavirus infection, as described herein, may refer to an infection in any part of the individual's (body), in particular the respiratory and gastrointestinal tracts or part(s) thereof.
In an embodiment, the compound provided by the invention is used in a method of therapy and/or (in vivo) diagnostics. The method of therapy and/or (in vivo) diagnostics is a method of detecting and/or treating a viral infection, particularly in the treatment of one or more viral infections caused by virulent virions, such as coronavirus. The compound may be used in the preparation of a medicament for detecting and/or treating a viral infection, particularly for treating one or more viral infections caused by virulent virions, such as coronavirus. Any other known medicament, compound, or composition used for the treatment of a viral infection can be used in co-therapy, co-administration or co-formulation with the compound.
In another embodiment, the compound provided by the invention 1s used for the manufacture of a medicament, such as a medicament for therapy and/or (in vivo) diagnostics. In particular, the compound as described herein is used for the manufacture of a medicament for the treatment of one or more viral infections caused by coronavirus. Preferably, the compound is used for the manufacture of a medicament for the treatment of viral infections caused by virulent virions, such as coronavirus.
There is also provided the compound provided by the invention for use in the prevention or treatment of a viral infection, comprising administering to a subject in need thereof the compound. The administering of the compound may be performed for a time sufficient to treat the viral infection. In particular, the viral infection may be caused by a virulent coronavirus, such as a severe acute respiratory syndrome-related coronavirus or a Middle East respiratory syndrome-related coronavirus. The compound may be used to treat a viral infection, comprising administering to a subject, preferably a subject in need thereof, the compound.
There are also provided methods of treating viral infections. In an embodiment, the method comprises administering to a subject with a viral infection, or a subject suspected of having a viral infection the compound according to the invention. In particular, the subject is in need of treatment of coronavirus infection(s), such as severe acute respiratory syndrome-related coronavirus infection or Middle East respiratory syndrome-related coronavirus infection. The treatment of viral infections can be targeted against virions and/or virus. In particular, the compound selectively targets virions.
There is further provided a method for inhibiting infection of a cell that is permissive for coronavirus, comprising: - providing the cell with a compound as described herein or a pharmaceutical composition as described herein.
In particular, the cell is provided with a therapeutic effective amount of the compound or pharmaceutical composition. The cell preferably expresses a receptor for the coronavirus. In one embodiment the receptor is the ACE2 virus receptor. A coronavirus such as the SARS-CoV-2 has been shown to enter cells that do not express ACE2. Such infections are also thought to be dependent on the spike protein. A compound as described herein because of the interaction with the spike protein may also inhibit such infections. There is further provided a method for treating an infection caused by coronavirus in an individual, comprising: - administering a compound as described herein or a pharmaceutical composition as described herein. In particular, the individual is in need for treatment of coronavirus infection.
There is further provided a method for treating an infection caused by a virus that can enter a cell via the ACE2 receptor, preferably a coronavirus in an individual, comprising:
- administering a compound as described herein or a pharmaceutical composition as described herein. In particular, the individual is in need for treatment of coronavirus infection.
In a further embodiment, the compound according to the invention is for use in the diagnosis of a disease caused by a virus, especially virulent coronavirus, such as severe acute respiratory syndrome-related coronavirus or Middle East respiratory syndrome-related coronavirus. The compound may be used in the preparation of a medicament for diagnosing a coronavirus disease, such as COVID-19.
In another embodiment, a method is provided of diagnosing a disease in a subject, comprising administering to the subject the compound according to the invention. In particular, the disease may be caused by a virulent coronavirus, such as a severe acute respiratory syndrome-related coronavirus or Middle East respiratory syndrome-related coronavirus.
In another embodiment, the compound according to the invention is used, preferably as medicament, in (a method for) the treatment of an individual. The compound may be used in the manufacture of a medicament for the treatment of an individual.
The compounds as described herein may be administered in any conventional manner by any route where the compound is active or becomes active. Administration can be systemic, topical or oral. Preferably, the administration is by one or more of depot injection, nebulization/inhalation, intravenous, and subcutaneous. The modus of administration may depend on the conditions or disease to be targeted or treated. The selection of the specific route of administration can be selected or adjusted by the clinician according to methods known to the clinician to obtain the desired clinical response. It may be desirable to administer one or more of the compounds locally to an area suitable for treatment, such as an area in need of treatment.
The compound as described herein may be administered either alone or in combination (concurrently or serially) with other compounds, such as pharmaceutically acceptable compounds and/or prodrugs. For example, the compound may be administered in combination with other analgesics, antidepressants, anti-anxiety compounds, anti-overactive bladder compounds, antibiotics, and/or compounds for the treatment of coronavirus infections.
The amount of compound as described herein to be administered is that amount which is therapeutically effective. The dosage to be administered will depend on the characteristics of the individual being treated, e.g., the particular species treated, age, weight, health, types of concurrent treatment, if any, and frequency of treatments, and can be easily determined by, e.g., a clinician. The dosage of the compounds as described herein can be used and adjusted depending upon the factors above. The selection of the specific dose regimen can be selected or adjusted or titrated by a clinician according to methods known in the art to obtain the desired clinical response.
The amount of the compound as described herein that will be effective in the treatment and/or prevention of a particular disease, condition or disorder, will depend on the nature and extent of the disease, condition or disorder, and can be determined by standard clinical techniques. In addition, e.g., in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disorder, and should be decided according to the judgment of the practitioner and the patient's condition(s). Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems (animal models).
The compound as described herein can be formulated for parenteral administration by injection. Formulations for injection can be presented in unit dosage form, such as in ampoules or in multi-dose containers, with an optionally added preservative or stabilizing agent. The compounds can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents, such as suspending, stabilizing and/or dispersing agents. In some embodiments, the injectable is in the form of a short-acting, depot or implant. In some embodiments, the parenteral dosage form is the form of a solution, suspension, emulsion, or dry powder.
For oral administration, the compound as described herein can be formulated by combining the compounds with pharmaceutically acceptable carriers. Such carriers enable the compounds to be formulated, for example, as tablets, pills, dragées, capsules, emulsions, liquids, gels, syrups, caches, pellets, powders, granules, slurries, lozenges, aqueous or oily suspensions, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by, for example, adding a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragées. Suitable excipients include, but are not limited to, fillers such as sugars, including, but not limited to, lactose, sucrose, mannitol, and sorbitol; cellulose preparations such as, but not limited to, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and polyvinyl pyrrolidone. If desired, disintegrating agents can be added, such as, but not limited to, the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
Orally administered compositions can contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents, such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compounds.
Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
Such vehicles are suitably of pharmaceutical grade.
Dragées can be provided with suitable coatings.
For this purpose, concentrated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments can be added to the tablets or dragée coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical preparations which can be used orally include, but are not limited to, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
In addition, stabilizers can be added.
For buccal administration, the compositions can take the form of, such as, tablets or lozenges formulated in a conventional manner.
For administration by inhalation, the compounds as described herein can be delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, such as gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The compound according to the invention can be present in a cream, solution, powder, fluid emulsion, fluid suspension, semi-solid, ointment, paste, gel, jelly, and foam, or in a patch containing any of the same. The compound can be formulated as a depot preparation. Such long acting formulations can be administered by implantation or by injection.
Thus, for example, the compound can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. The compound can be contained in formulations with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives or the like.
The pharmaceutical composition as described herein can comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
In some embodiments, the compound according to the invention is used with agents, such as topical analgesics, barrier devices, or rinses. In other embodiments, the compound is delivered in a vesicle, in particular a liposome.
In some embodiments, the compound according to the invention is lyophilized to a solid and reconstituted with, for example, water prior to use. When administered to a mammal (e.g., to an animal for veterinary use or to a human for clinical use) the compound can be administered in isolated form. When administered to a human, the compound can be sterile. Water is a suitable carrier when the compound is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, tale, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, dimethyl sulfoxide, and ethanol. Compositions comprising the compound, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
The compound as described herein and/or compositions containing the compound can take the form of a solution, suspension, emulsion, tablet, pill, pellet, capsule, capsule containing a liquid, powder, sustained-release formulation, suppository, aerosol, spray, or any other form suitable for use.
In some embodiments, the compound according to the invention is formulated in accordance with routine procedures as a pharmaceutical composition adapted for administration to, in particular humans. Typically, the compound can be in the form of a solution in a sterile isotonic aqueous buffer. Where necessary, the composition can also include a solubilizing agent. Compositions for intravenous administration may optionally include a local anesthetic such as lidocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachets indicating the quantity of active agent. Where the compound is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compound is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
The compounds and (pharmaceutical) compositions, comprising a compound as described herein, can be in unit dosage form. In such form, the compound can be divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
In some embodiments, a composition comprising the compound according to the invention is in the form of a liquid wherein the active agent 1s the compound. For example, the compound may be present in solution, 1n suspension, as an emulsion, or as a solution/suspension. The liquid composition may be in the form of a gel. The liquid composition may be aqueous. The composition may be in the form of an ointment.
In an embodiment, an isotope carrier is provided comprising the compound according to the invention, wherein the compound comprises one or more stable nuclides. The isotope carrier may be suitable for diagnostics in that the presence of the isotope carrier can be detected, for example, when used in vivo. Suitable stable nuclides include deuterium, 13C, 15N, 83S, MS, 36S, 170, and 180.
In an embodiment, a pharmaceutical kit is provided comprising one or more containers filled with one or more compounds according to the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration for treating a condition, disease, or disorder described herein, preferably coronavirus infection. In some embodiments, the kit contains more than one compound as described herein.
In some embodiments, the individual compounds as depicted herein are provided. These compounds may be used in medical applications, such as in medicine. The compounds may be used for treating medical disorders (z.e., diseases, conditions or symptom s)), especially coronavirus disease, such as COVID-19. The compounds may be used in any method as described herein, such as a method of therapy and/or (in vivo) diagnostics, in particular to detect and/or treat viral infection, especially in the treatment of one or more viral infections caused by virulent coronaviruses, such as SARS-CoV, SARS-CoV-2 or MERS-CoV.
The invention has been described by reference to various embodiments, and methods. The skilled person understands that features of various embodiments and methods can be combined with each other.
All references cited herein are hereby completely incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising”, “having”, “including” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. For the purpose of the description and of the appended claims, except where otherwise indicated, all numbers expressing amounts, quantities, percentages, and so forth, are to be understood as being modified in all instances by the term “about”. Also, all ranges include any combination of the maximum and minimum points disclosed and include any intermediate ranges therein, which may or may not be specifically enumerated herein. Preferred embodiments of this invention are described herein.
Variation of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject-matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. The claims are to be construed to include alternative embodiments to the extent permitted by the prior art.
For the purpose of clarity and a concise description features are described herein as part of the same or separate embodiments, however, it will be appreciated that the scope of the invention may include embodiments having combinations of all or some of the features described. The invention will now be further illustrated by the following non-limiting examples.
Examples Example 1 - Synthesis of Id-C1, Id-N1 All solvents used were degassed before use by purging the solvents with argon for 30 min.
To an ammonium carbonate buffer solution (20 mM, pH 7.9) was added 0.5 mM of 1,1',1"-(1,3,5-tr1azinane-1,3,5-triyDtrzs(2-bromoethanone) (TATB, 125 ul, 2 mM in MeCN) and 4 mM of the respective thiol-peptide (200 nl, 10 mM in water) which resulted in a MeCN : buffer solution (1: 3, 500 pl). The mixture was incubated for 2 h at 25 °C and 600 rpm.
After reaching full conversion, the product was purified by means of A) SulfoLink Coupling resin under reductive conditions, and/or B) preparative reversed phase HPLC using a gradient of MeCN and H:0 (0.1 % TFA). Example 2 - Synthesis of Id-C2, Id-N2 All solvents used were degassed before used by purging the solvents with argon for 30 min.
A solution of 1 mM of 1,11-bismaleimido-triethyleneglycol (2 ul at 5 mM in DMSO) and 2.1 mM of the respective thiol-peptide (0.9 ul, 20 mM in water) in PBS (pH 7.4) was incubated for 3 h at 25 °C and 600 rpm.
After reaching full conversion, the product was purified by means of A) SulfoLink Coupling resin under reductive conditions, and/or B) preparative reversed phase HPLC using a gradient of MeCN and H20 (0.1 % TFA). Example 2 - Synthesis of Id-C3, Id-N3 The respective azide-peptide was dissolved in DMF / H:0 (2 : 1, 4 mM) and to this 1 mM tripropargylamine (100 mM in DMF) was added.
To this was added a pre-incubated mixture of CuSO4 (6 mM), THPTA-ligand (6 mM) and sodium ascorbate (30 mM) in H2O was added.
After full completion of the reaction 30 mM EDTA-solution was added (0.1 M in water). The mixture was purified by preparative reversed phase HPLC using a gradient of MeCN and HsO (0.1 % TFA).
As an illustrative example for each of the synthesis examples, Figure 3 shows the characterization of Id-N2 (C-terminal acid, R+= OH).
Figure 3A shows the HPLC chromatogram of Id-N2. Eluent a is water, eluent b is acetonitrile (each with 1 % formic acid and 0.01 % trifluoroacetic acid). The eluent used for the HPLC corresponds to 0-2 min 5 % of eluent a and 95 % eluent b, followed by 2-6 min linear gradient 5 % to 95% of eluent a and 95 % to 5 % eluent b.
Figure 3B shows an electrospray ionization mass spectrometry (ESI MS) spectrum with calculated signals: 812 (9+), 914 (8+), 1044 (7+), 1218 (6+), 1461 (5+), 1827 (4+).
2025303SEQcdrom (2)
SEQUENCE LISTING <110> Stichting VU <120> CORONAVIRUS TARGETING DRUGS <130> P126846NL00 <140> NL 2025303 <141> 2020-04-08 <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> peptide <400> 1 Thr Phe Leu Asp Lys Phe Asn His Glu Ala Glu Asp Leu Phe Tyr Gln 1 5 10 15 <210> 2 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> peptide <400> 2 Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala 1 5 10 15 Glu Asp Leu Phe Tyr Gln Ser Ser Leu Ala <210> 3 <211> 7 <212> PRT <213> Homo sapiens Pagina 1
2025303SEQcdrom (2) <400> 3 Leu Gly Lys Gly Asp Phe Arg 1 5 <210> 4 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> peptide <400> 4 Leu Gly His Lys Gly Asp Phe Arg 1 5 <210> 5 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> peptide <400> 5 Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala 1 5 10 15 Glu Asp Leu Phe Tyr Gln Ser Ser Gly Leu Gly Lys Gly Asp Phe Arg
<210> 6 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> peptide <220> <221> MOD_RES <222> (25)..(25) <223> bAla Pagina 2
2025303SEQcdrom (2) <400> 6 Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala 1 5 10 15 Glu Asp Leu Phe Tyr Gln Ser Ser Ala Leu Gly Lys Gly Asp Phe Arg
<210> 7 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> peptide <400> 7 Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala 1 5 10 15 Glu Asp Leu Phe Tyr Gln Ser Ser Gly Gly Leu Gly Lys Gly Asp Phe 20 25 30 Arg <2105 8 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> peptide <220> <221> MOD_RES <222> (26)..(26) <223> lysine with PEG moiety attached to side chain, including thiol modification <400> 8 Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala 1 5 10 15 Pagina 3
2025303SEQcdrom (2) Glu Asp Leu Phe Tyr Gln Ser Ser Gly Xaa Leu Gly Lys Gly Asp Phe
Arg <216> 9 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> peptide <220> <221> MOD_RES <222> (25)..(25) <223> lysine with PEG moiety attached to side chain, including thiol modification <400> 9 Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala 1 5 10 15 Glu Asp Leu Phe Tyr Gln Ser Ser Xaa Gly Leu Gly Lys Gly Asp Phe 20 25 30 Arg Pagina 4
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2025303A NL2025303B9 (en) | 2020-04-08 | 2020-04-08 | Coronavirus targeting drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2025303A NL2025303B9 (en) | 2020-04-08 | 2020-04-08 | Coronavirus targeting drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
NL2025303B1 NL2025303B1 (en) | 2021-10-25 |
NL2025303B9 true NL2025303B9 (en) | 2022-04-06 |
Family
ID=70918925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2025303A NL2025303B9 (en) | 2020-04-08 | 2020-04-08 | Coronavirus targeting drugs |
Country Status (1)
Country | Link |
---|---|
NL (1) | NL2025303B9 (en) |
-
2020
- 2020-04-08 NL NL2025303A patent/NL2025303B9/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NL2025303B1 (en) | 2021-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10562934B2 (en) | Modulation of complement activity | |
US11707503B2 (en) | Modulators of complement activity | |
CN103533949B (en) | As ischemic brain injury effective neuroprotective and be used for the treatment of two polygalacturonase inhibitors of the high-affinity of the PSD-95 of pain | |
RU2676713C2 (en) | Therapeutic peptides | |
JP2020532496A (en) | High affinity CXCR4 selective binding conjugate and how to use it | |
US20230372551A1 (en) | Radiolabeled ligands for targeted pet/spect imaging and methods of their use | |
WO2014144768A2 (en) | Bh4 stabilized peptides and uses thereof | |
NL2025303B9 (en) | Coronavirus targeting drugs | |
US10881708B2 (en) | Ang (1-7) derivative oligopeptides for the treatment of pain | |
AU2018314833B2 (en) | Novel compounds activating the NRF2 pathway | |
JP2020059663A (en) | Peptides or pharmaceutically acceptable salts thereof or prodrugs thereof | |
JPWO2018030432A1 (en) | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | |
US20230203107A1 (en) | Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis | |
CN117062826A (en) | Antiinfective bicyclic peptide ligands | |
CN117083287A (en) | Antiinfective bicyclic peptide ligands | |
JP2018154565A (en) | Peptide and antitumor agent | |
WO2018156801A2 (en) | Peptides and methods of treating dystrophy-related disorders using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TK | Erratum |
Effective date: 20220413 |
|
MM | Lapsed because of non-payment of the annual fee |
Effective date: 20230501 |